Sumitomo treats first patient in Phase I/IIa trial of DSP-3077

The study will assess the tolerability and safety of two dose levels of DSP-3077 delivered via a single subretinal injection.

Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa

MARLBOROUGH, Mass.-- (BUSINESS WIRE)--Aug 12, 2026-- ...
electrive

Sumitomo Chemical aims to make solid-state batteries more affordable

Sumitomo Chemical has developed a solid-electrolyte battery in collaboration with Kyoto University and Tottori University. The technology is based on halides and uses chlorine, among other elements.
Nikkei Asia

Sumitomo Chemical to mass-produce solid-state battery material for EVs

TOKYO -- Sumitomo Chemical plans to begin mass production of a new electrolyte material for solid-state batteries that shows promise for electric vehicles as early as fiscal 2028, a move expected to ...